JP2025134747A5 - - Google Patents

Info

Publication number
JP2025134747A5
JP2025134747A5 JP2025095960A JP2025095960A JP2025134747A5 JP 2025134747 A5 JP2025134747 A5 JP 2025134747A5 JP 2025095960 A JP2025095960 A JP 2025095960A JP 2025095960 A JP2025095960 A JP 2025095960A JP 2025134747 A5 JP2025134747 A5 JP 2025134747A5
Authority
JP
Japan
Prior art keywords
lou064
patient
use according
pharmaceutical composition
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025095960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025134747A (ja
Filing date
Publication date
Priority claimed from PCT/IB2023/051787 external-priority patent/WO2023161887A1/en
Application filed filed Critical
Publication of JP2025134747A publication Critical patent/JP2025134747A/ja
Publication of JP2025134747A5 publication Critical patent/JP2025134747A5/ja
Pending legal-status Critical Current

Links

JP2025095960A 2022-02-28 2025-06-09 化膿性汗腺炎の治療における使用のためのレミブルチニブ Pending JP2025134747A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263314572P 2022-02-28 2022-02-28
US63/314,572 2022-02-28
US202263369016P 2022-07-21 2022-07-21
US63/369,016 2022-07-21
PCT/IB2023/051787 WO2023161887A1 (en) 2022-02-28 2023-02-27 Remibrutinib for use in the treatment of hidradenitis suppurativa
JP2023553381A JP7696006B2 (ja) 2022-02-28 2023-02-27 化膿性汗腺炎の治療における使用のためのレミブルチニブ

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023553381A Division JP7696006B2 (ja) 2022-02-28 2023-02-27 化膿性汗腺炎の治療における使用のためのレミブルチニブ

Publications (2)

Publication Number Publication Date
JP2025134747A JP2025134747A (ja) 2025-09-17
JP2025134747A5 true JP2025134747A5 (https=) 2026-03-06

Family

ID=85570288

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023553381A Active JP7696006B2 (ja) 2022-02-28 2023-02-27 化膿性汗腺炎の治療における使用のためのレミブルチニブ
JP2025095960A Pending JP2025134747A (ja) 2022-02-28 2025-06-09 化膿性汗腺炎の治療における使用のためのレミブルチニブ

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2023553381A Active JP7696006B2 (ja) 2022-02-28 2023-02-27 化膿性汗腺炎の治療における使用のためのレミブルチニブ

Country Status (11)

Country Link
US (1) US20250099465A1 (https=)
EP (1) EP4486346A1 (https=)
JP (2) JP7696006B2 (https=)
KR (1) KR20240155278A (https=)
CN (1) CN120617264A (https=)
AU (1) AU2023225222A1 (https=)
CA (1) CA3251002A1 (https=)
IL (1) IL314205A (https=)
MX (1) MX2024010392A (https=)
TW (1) TW202342048A (https=)
WO (1) WO2023161887A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250243170A1 (en) * 2024-01-26 2025-07-31 Novartis Ag Remibrutinib drug substance and drug product substantially free of nitrosamine impurity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
CR20180285A (es) 2015-11-26 2018-07-16 Novartis Ag Derivados novedosos de diamino piridina
RU2749547C2 (ru) 2016-09-23 2021-06-15 Новартис Аг Индазольные соединения для применения при повреждениях сухожилий и/или связок
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
EP3849559A4 (en) * 2018-09-12 2022-06-01 Denovo Biopharma LLC COMBINATION OF ENZASTAURIN AND INHIBITORS OF BTK AND USES THEREOF
RS67141B1 (sr) 2019-05-23 2025-09-30 Novartis Ag Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije
CN113840821A (zh) 2019-05-23 2021-12-24 诺华股份有限公司 Btk抑制剂的晶型
BR112021023110A2 (pt) 2019-05-23 2022-04-12 Novartis Ag Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton
AU2021205248A1 (en) * 2020-01-08 2022-09-01 Principia Biopharma Inc. Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile
MX2023008671A (es) 2021-01-26 2023-09-25 Novartis Ag Composicion farmaceutica.

Similar Documents

Publication Publication Date Title
JP5715101B2 (ja) ピルフェニドンおよび薬学的に受容可能な賦形剤のカプセル処方物
CN106413712B (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物
TW202116303A (zh) α—1抗胰蛋白酶缺乏症之治療方法
JP2025134747A5 (https=)
JP2024178420A5 (https=)
JP7701757B2 (ja) タウロデオキシコール酸またはその薬学的に許容される塩を有効成分として含む新型コロナウイルス感染症(covid-19)の治療用組成物
CA2442410A1 (en) Duloxetine for treatment of hot flashes
JP2003525899A (ja) 乾癬の治療
EP3616697A1 (en) Use of a pharmaceutical carrier in the preparation of an anti-diabetic pharmaceutical composition
JP2004091473A (ja) 色素沈着改善治療薬
WO2008057464A2 (en) Compositions and methods for improving the bioavailability of liothyronine
TW200951117A (en) Combination of dronedarone with at least one diuretic, therapeutic application thereof
JP2018528238A (ja) 円形脱毛症の治療
JP6959478B1 (ja) ポルフィリン症の予防又は治療剤
WO2014131360A1 (zh) 普罗布考及其衍生物抗肿瘤转移的用途
US20040152733A1 (en) Duloxetine for treatment of hot flashes
JP2025506869A (ja) 特発性肺線維症の処置のための組成物及び方法
EP3766496B1 (en) Anlotinib for treatment of nasopharyngeal carcinoma
JP2023503844A (ja) 乾癬を治療する漢方薬組成物、その製造方法及び使用
WO2023220396A1 (en) Methods of treatment using a dual specificity tyrosine-phosphorylation-regulated kinase 1a (dyrk1a) inhibitor
CN110664799B (zh) 用于治疗脑缺血的药物组合物及其应用
JPH10175852A5 (https=)
CN112826820B (zh) Nlrp3抑制剂及其应用
CN111035763A (zh) 一种治疗妇女更年期综合症的药物组合物
TW202214249A (zh) 紫質症之預防或治療劑